MSB 1.29% $1.18 mesoblast limited

Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment, page-216

  1. 235 Posts.
    lightbulb Created with Sketch. 120
    If overwhelming efficacy is demonstrated at an interim readout then the trial has to be halted and the placebo patients offered the treatment. Clearly immoral not to do so ... also a legal minefield if this was not done.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.18
Change
0.015(1.29%)
Mkt cap ! $1.347B
Open High Low Value Volume
$1.15 $1.20 $1.15 $4.551M 3.886M

Buyers (Bids)

No. Vol. Price($)
2 98246 $1.17
 

Sellers (Offers)

Price($) Vol. No.
$1.18 19079 2
View Market Depth
Last trade - 16.10pm 16/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.